## **Without Cirrhosis**

TABLE 124: SVR GENOTYPE 2 WITHOUT CIRRHOSIS TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR24	1.16 (1.08 to 1.24)	13.13 (7.11 to 18.84)
SOF12 + PR12		1.15 (0.48 to 1.27)	12.24 (-42.72 to 20.81)
SOF12 + PR12	SOF12 + RBV12	0.99 (0.41 to 1.07)	-0.56 (-55.44 to 6.59)
Random effect model	Residual deviance	3.912 vs. 6 data points	
	Deviance information criteria	18.761	
Fixed effect model	Residual deviance	3.841 vs. 6 data points	
	Deviance information criteria	18.66	

CrI = credible interval; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.